SGRY - Surgery Partners reaffirms FY22 guidance January, 09 2023 08:02 AM Surgery Partners Inc. Surgery Partners ( NASDAQ: SGRY ) re-affirms its 2022 Adjusted EBITDA guidance of $375M to $385M. 2022 revenue expected of $2.50B to $2.55B vs consensus of $2.52B . For further details see: Surgery Partners reaffirms FY22 guidance